Idiopathic is a term used to describe a condition that is not treatable. With the discovery of many clinical subtypes and pathogenic causes, Parkinson's Disease as a single entity has been questioned. Putative causative environmental agents, as well as chromosomes. Non-motor symptoms may accompany classic motor symptoms. Dopaminergic, noradrenergic, glutamatergic, and other neurotransmitters are all involved. The pathways of serotonin and adenosine provide information. Through the plethora of clinical phenomenology linked with Parkinson’s disease and the prospect of alternative therapies, Dopamine-based therapies aren’t the only one’s available therapies to replace the original. The lack of accurate and responsive biomarkers of progression has been one of the most challenging challenges in the production of potential neuroprotective therapies. Immunotherapies that target aggregated, toxic-synuclein, such as vaccination or monoclonal antibodies. Clinical studies are currently looking at anti-aggregation and protein clearance techniques. The use of glucagon-like peptide one receptor agonists, unique PD gene target agents (such as GBA or LRRK2 modifiers), and other potential disease-modifying drugs gives reason to be cautiously optimistic that more successful therapies are on the way. Patients with Parkinson’s disease should have hope for their potential results and prognosis thanks to modern symptomatic treatments, advanced drug delivery technologies, and experimental surgical interventions. In clinical practice, the word “idiopathic” PD has traditionally been used to identify the most common cause of parkinsonism. However, with the discovery of monogenic types of Parkinson’s disease (which may be clinically indistinguishable from the ‘idiopathic’ form), the clinical heterogeneity of the disease, and the clinical overlap between PD dementia, dementia with Lewy bodies, and other forms of parkinsonism, the disease's clinical heterogeneity and clinical overlap between PD dementia, dementia with Lewy bodies, and other forms of parkinsonian, the disease's clinical heterogeneity. Traditionally, the possible cause and effect relationship between etiologic factors and disease has been investigated using cross-sectional (hospital and community) clinical association research. Methodologies may be community-based or prospective (population-based). Pesticides have been implicated as one of the risk factors and heavy metal exposure, as well as rural living and agricultural work traumatic brain injury dairy products, type 2 diabetes mellitus. The two most consistent protective factors linked to a lower risk of Parkinson's disease are cigarette smoking and caffeine intake. Higher serum urate, for example, has also been linked. Usage of ibuprofen and exercise, for example, the connection between cigarette smoking and Parkinson's disease is particularly intriguing. This inverse relationship is difficult to understand, but there are some hypotheses that have said that PD-relatives. PD is a complex neurodegenerative disease with a wide range of motor and non-motor symptoms that necessitates a tailored treatment strategy. Clinical studies that are intended to include evidence-based results must provide a well-defined patient and control group, as well as the most objective, accurate, and validated methods for assessing the therapeutic intervention’s effects. While a number of clinical rating scales and other instruments have been used to determine response to different treatments, the UPDRS is the most commonly used as the primary outcome indicator in clinical trials. It is important to recognize the variable slopes of progression in patients with PD, which represent the clinical (and pathological) heterogeneity of the condition, in order to consider disease-modifying therapies.

*Address for Correspondence: Sharvari Desai, Lovely Professional University, Jalandhar, India. Email: iamSharvari23@gmail.com

Copyright: © 2021 Desai S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received 05 March, 2021; Accepted 12 March, 2021; Published 26 March, 2021